Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin Pharmaceutical (BMRN), Agios Pharma (AGIO) and
Agios Pharma (AGIO) Gets a Buy Rating from Canaccord Genuity
10:08am, Friday, 01'st May 2020
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Agios Pharma (AGIO), with a price target of $72.00. The
Agios Pharma (AGIO) Gets a Buy Rating from Canaccord Genuity
10:08am, Friday, 01'st May 2020
In a report released yesterday,
John Newman
from Canaccord Genuity maintained a
Buy
rating on Agios Pharma (
AGIO
–
Research Report
), with a price target of
$72.00
. The company’s shares closed l
FY2024 Earnings Forecast for Agios Pharmaceuticals Inc (NASDAQ:AGIO) Issued By SVB Leerink
09:30am, Friday, 01'st May 2020
Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Investment analysts at SVB Leerink decreased their FY2024 earnings estimates for Agios Pharmaceuticals in a report issued on Monday, April 27th. SVB Leerink
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Forecasted to Earn Q2 2020 Earnings of ($1.85) Per Share
06:26am, Friday, 01'st May 2020
Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Research analysts at SVB Leerink boosted their Q2 2020 earnings estimates for Agios Pharmaceuticals in a note issued to investors on Monday, April 27th. SVB
Agios Pharmaceuticals Inc (AGIO) Q1 2020 Earnings Call Transcript
05:30am, Friday, 01'st May 2020
AGIO earnings call for the period ending March 31, 2020.
Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat
12:00am, Friday, 01'st May 2020Edited Transcript of AGIO earnings conference call or presentation 30-Apr-20 12:00pm GMT
10:15pm, Thursday, 30'th Apr 2020
Q1 2020 Agios Pharmaceuticals Inc Earnings Call
Oppenheimer Maintains Their Hold Rating on Agios Pharma (AGIO)
08:36pm, Thursday, 30'th Apr 2020
Oppenheimer analyst Mark Breidenbach maintained a Hold rating on Agios Pharma (AGIO) today. The company's shares closed last Thursday at $41.14. According
Oppenheimer Maintains Their Hold Rating on Agios Pharma (AGIO)
08:36pm, Thursday, 30'th Apr 2020
Oppenheimer analyst
Mark Breidenbach
maintained a
Hold
rating on Agios Pharma (
AGIO
–
Research Report
) today. The company’s shares closed last Thursday at $41.14.
According to
TipRanks.com
, Bre
Agios Pharma S-3 Shows Registration For Mixed Securities Shelf Offering, No Size Disclosed
08:28pm, Thursday, 30'th Apr 2020Agios Pharmaceuticals, Inc.'s (AGIO) CEO Jacqualyn Fouse on Q1 2020 Results - Earnings Call Transcript
06:51pm, Thursday, 30'th Apr 2020
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2020 Results Earnings Conference Call April 30, 2020, 08:00 AM ET Company Participants Holly Manning - Director of
Agios Pharma (AGIO) Gets a Buy Rating from Needham
03:27pm, Thursday, 30'th Apr 2020
In a report released today, Chad Messer from Needham maintained a Buy rating on Agios Pharma (AGIO), with a price target of $71.00. The company's shares
Agios Pharma (AGIO) Gets a Buy Rating from Needham
03:27pm, Thursday, 30'th Apr 2020
In a report released today,
Chad Messer
from Needham maintained a
Buy
rating on Agios Pharma (
AGIO
–
Research Report
), with a price target of
$71.00
. The company’s shares closed last Thursday a
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
01:05pm, Thursday, 30'th Apr 2020
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 65.29% and 182.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
